Fisher BA, Mariette X, Papas A, Grader-Beck T, et al. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet 2024;404:540-553.
PMID: 39096929